Donor-Derived Cell-Free DNA Testing in Kidney Transplantation: Do One-Month Values Have Any Prognostic Significance?
1ATRIUM HEALTH Wake Forest Baptist Medical Center, Winston Salem, NC, 2Wake Forest Baptist Medical Center, Winston Salem, NC, 3Wake Forest Baptist Health, Winston-Salem, NC
Meeting: 2022 American Transplant Congress
Abstract number: 629
Keywords: Rejection
Topic: Basic Science » Basic Science » 02 - Acute Rejection
Session Information
Session Time: 5:30pm-7:00pm
Presentation Time: 5:30pm-7:00pm
Location: Hynes Halls C & D
*Purpose: Plasma-based donor-derived cell-free DNA (dd-cfDNA) assays have been proposed as an alternative to percutaneous renal allograft biopsy which is the current gold standard for detecting acute rejection after kidney transplantation (KT). We examined the value of dd-cfDNA testing at 1 month following KT.
*Methods: We performed a single center retrospective review of all adult KT patients (pts) who underwent dd-cfDNA testing between January 2018 and August 2021. The diagnosis of acute rejection was based on histopathology obtained from percutaneous needle biopsies. Our center’s standard practice included dd-cfDNA testing and performing surveillance kidney biopsies at 1 month following KT. The dd-cfDNA test was considered elevated if >1.0%.
*Results: During the study period, 3157 dd-cfDNA tests were performed in 695 de novo pts. Higher mean 1-month dd-cfDNA levels were noted in the following categories: Retransplants (n=30, 1.8±2.1); highly sensitized pts (PRA 98-100%, n=27, 1.6±2.0; for highly sensitized retransplants, n=18, 2.0±2.3; for highly sensitized primary KTs, n=9, 0.7±0.5); and pts who underwent early reoperations (n=16, 0.85±0.9). In all other KT categories, mean 1-month dd-cfDNA levels were lower and similar: DCD donor KTs (n=53, 0.56±0.4), living donor KTs (n=51, 0.47±0.4); acute kidney injury (AKI) donor KTs (n=23, 0.47±0.6); standard criteria donor (SCD) KTs (n=91, 0.47±0.4); expanded criteria donor (ECD) KTs (n=44, 0.46±0.5); dual KTs (n=16, 0.45±0.4); and pts with delayed graft function (DGF, n=50, 0.46±0.4). In 58 primary KT pts with negative 1-month surveillance biopsies, corresponding mean 1-month dd-cfDNA levels were 0.49±0.4. In 10 pts with positive 1-month surveillance biopsies, corresponding mean 1-month dd-cfDNA levels were 1.5±1.8. In 26 pts with a 1-month dd-cfDNA level >1.0, the subsequent incidence of acute rejection was 27%; in 22 pts with a 1-month dd-cfDNA level ≥2.0, the subsequent incidence of acute rejection was 50% (mean follow-up 14 months).
*Conclusions: We noted a bimodal distribution of 1-month dd-cfDNA levels. Higher mean 1-month dd-cfDNA levels (range 0.72-2.2) were associated with retransplants, high PRA pts, and pts with early reoperations; 22-44% of pts in these categories had 1-month dd-cfDNA levels >1.0. Conversely, primary KT alone pts (DCD, living donor, AKI donor, SCD, ECD, dual KT, those with DGF) had lower 1-month dd-cfDNA levels (range 0.45-0.56) and only 7-14% had 1-month dd-cfDNA levels >1.0. One-month surveillance biopsy results correlated with corresponding dd-cfDNA levels.
To cite this abstract in AMA style:
Sharda BK, Garner M, Farney A, Orlando G, Rogers J, Jay C, Daniel A, Guiterrez A, Sakhovskaya N, Stratta R. Donor-Derived Cell-Free DNA Testing in Kidney Transplantation: Do One-Month Values Have Any Prognostic Significance? [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/donor-derived-cell-free-dna-testing-in-kidney-transplantation-do-one-month-values-have-any-prognostic-significance/. Accessed September 7, 2024.« Back to 2022 American Transplant Congress